Details of the Drug

General Information of Drug (ID: DMYX7NI)

Drug Name
Acetohydroxamic Acid
Synonyms
AHA; Acethydroxamsaeure; Acethydroxamsaure; Acetohydroxamate; HAE; Lithostat; Acethydroxamic acid; Acethydroxamsaeure [German]; Acetohydroximic acid; Acetyl hydroxyamino; Acetylhydroxamic acid; Acide acetohydroxamique; Acide acetohydroxamique [French]; Acido acetohidroxamico; Acido acetohidroxamico [Spanish]; Acidum acetohydroxamicum; Acidum acetohydroxamicum [Latin]; Cetohyroxamic acid; Methylhydroxamic acid; SJX HLdmMAH; AHA (TN); Acetic acid, oxime; Acetohydroxamic acid [USAN:INN]; Lithostat (TN); N-Acetyl hydroxyacetamide; N-Acetylhydroxylamine; N-Hydroxyacetamide; N-hydroxyacetimidic acid; N-hydroxyethanimidic acid; S14-0751; Acetohydroxamic acid (USP/INN); Acetamide, N-hydroxy-(9CI)
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [1]
Therapeutic Class
Antiinfective Agents
Affected Organisms
Enteric bacteria and other eubacteria
ATC Code
G04BX03: Acetohydroxamic Acid
G04BX: Other urologicals
G04B: UROLOGICALS
G04: UROLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 75.07
Logarithm of the Partition Coefficient (xlogp) -1.6
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Bioavailability
55% of drug becomes completely available to its intended biological destination(s) [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 10 hours [3]
Chemical Identifiers
Formula
C2H5NO2
IUPAC Name
N-hydroxyacetamide
Canonical SMILES
CC(=O)NO
InChI
InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
InChIKey
RRUDCFGSUDOHDG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1990
ChEBI ID
CHEMBL27777
CAS Number
546-88-3
UNII
4RZ82L2GY5
DrugBank ID
DB00551
TTD ID
D0R9BG
ACDINA ID
D00805
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Urease (Bact ureC) TTAS2UO URE1_KLEAE Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Acetohydroxamic Acid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Acetohydroxamic Acid and Ocrelizumab. Multiple sclerosis [8A40] [5]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Acetohydroxamic Acid and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [6]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Levomenthol E00248 16666 Flavoring agent
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Acetohydroxamic Acid 250mg tablet 250mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018749.
2 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121.
5 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
6 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.